NO20051847L - Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi. - Google Patents
Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi.Info
- Publication number
- NO20051847L NO20051847L NO20051847A NO20051847A NO20051847L NO 20051847 L NO20051847 L NO 20051847L NO 20051847 A NO20051847 A NO 20051847A NO 20051847 A NO20051847 A NO 20051847A NO 20051847 L NO20051847 L NO 20051847L
- Authority
- NO
- Norway
- Prior art keywords
- neurosis
- bulimia
- anorexia
- epa
- treatment
- Prior art date
Links
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title abstract 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 title abstract 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title abstract 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title abstract 4
- 208000032841 Bulimia Diseases 0.000 title abstract 2
- 206010006550 Bulimia nervosa Diseases 0.000 title abstract 2
- 206010029333 Neurosis Diseases 0.000 title abstract 2
- 208000022531 anorexia Diseases 0.000 title abstract 2
- 206010061428 decreased appetite Diseases 0.000 title abstract 2
- 208000015238 neurotic disease Diseases 0.000 title abstract 2
- 208000035850 clinical syndrome Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0221480.7A GB0221480D0 (en) | 2002-09-16 | 2002-09-16 | Treatment of anorexia nervosa (AN) and bulimia |
| PCT/GB2003/003985 WO2004024136A1 (en) | 2002-09-16 | 2003-09-16 | Eicosapentaenoic acid (epa) for treating anorexia nervosa (an) and bulimia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20051847L true NO20051847L (no) | 2005-04-15 |
Family
ID=9944164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20051847A NO20051847L (no) | 2002-09-16 | 2005-04-15 | Eikosapentaensyre (EPA) for behandling av anoreksia nevrosa (AN) og bulimi. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060135608A1 (enExample) |
| EP (1) | EP1556028A1 (enExample) |
| JP (1) | JP2006503031A (enExample) |
| KR (1) | KR20050042823A (enExample) |
| CN (1) | CN1694694A (enExample) |
| AU (1) | AU2003269138A1 (enExample) |
| BR (1) | BR0317857A (enExample) |
| CA (1) | CA2499142A1 (enExample) |
| GB (1) | GB0221480D0 (enExample) |
| HR (1) | HRP20050245A2 (enExample) |
| IS (1) | IS7744A (enExample) |
| MX (1) | MXPA05002943A (enExample) |
| NO (1) | NO20051847L (enExample) |
| NZ (1) | NZ538793A (enExample) |
| PL (1) | PL375726A1 (enExample) |
| RS (1) | RS20050226A (enExample) |
| RU (1) | RU2330653C2 (enExample) |
| TW (1) | TW200410682A (enExample) |
| WO (1) | WO2004024136A1 (enExample) |
| ZA (1) | ZA200502161B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
| WO2005046668A1 (ja) * | 2003-11-14 | 2005-05-26 | Mochida Pharmaceutical Co., Ltd. | 言語障害予防・治療剤 |
| JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
| JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および／又はうつ症状の改善作用を有する組成物 |
| KR101578498B1 (ko) | 2006-12-28 | 2015-12-18 | 산토리 홀딩스 가부시키가이샤 | 신경 재생제 |
| CA2672513C (en) | 2007-02-15 | 2010-05-25 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| BRPI1011883A2 (pt) * | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| AU2012214260A1 (en) * | 2011-02-11 | 2013-07-25 | E. I. Du Pont De Nemours And Company | An eicosapentaenoic acid concentrate |
| US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
| RU2545988C1 (ru) * | 2013-11-12 | 2015-04-10 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр Департамента здравоохранения города Москвы | Способ лечения хронического запора и функциональной анорексии |
| WO2019153073A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| US20210130897A1 (en) * | 2018-04-16 | 2021-05-06 | Quadrant Biosciences Inc. | Salivary microrna levels in anorexia nervosa provide a liquid biopsy of metabolic and neuropsychiatric status |
| US11166933B2 (en) | 2018-05-03 | 2021-11-09 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| CN109276262B (zh) * | 2018-07-30 | 2021-01-26 | 中国科学院心理研究所 | 一种用于筛选高危进食障碍的检测系统 |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| US12144786B2 (en) | 2020-03-27 | 2024-11-19 | Homeostasis Therapeutics LLC | Methods of treatment for anorexia nervosa, bulimia and related clinical syndromes |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9224809D0 (en) * | 1992-11-26 | 1993-01-13 | Scotia Holdings Plc | Schizophrenia |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
-
2002
- 2002-09-16 GB GBGB0221480.7A patent/GB0221480D0/en not_active Ceased
-
2003
- 2003-09-16 NZ NZ538793A patent/NZ538793A/en unknown
- 2003-09-16 RU RU2005107416/14A patent/RU2330653C2/ru not_active IP Right Cessation
- 2003-09-16 TW TW092125483A patent/TW200410682A/zh unknown
- 2003-09-16 PL PL03375726A patent/PL375726A1/xx not_active Application Discontinuation
- 2003-09-16 EP EP03750919A patent/EP1556028A1/en not_active Ceased
- 2003-09-16 KR KR1020057004483A patent/KR20050042823A/ko not_active Withdrawn
- 2003-09-16 CN CNA038251698A patent/CN1694694A/zh active Pending
- 2003-09-16 JP JP2004535695A patent/JP2006503031A/ja active Pending
- 2003-09-16 RS YUP-2005/0226A patent/RS20050226A/sr unknown
- 2003-09-16 US US10/528,114 patent/US20060135608A1/en not_active Abandoned
- 2003-09-16 AU AU2003269138A patent/AU2003269138A1/en not_active Abandoned
- 2003-09-16 HR HR20050245A patent/HRP20050245A2/hr not_active Application Discontinuation
- 2003-09-16 CA CA002499142A patent/CA2499142A1/en not_active Abandoned
- 2003-09-16 MX MXPA05002943A patent/MXPA05002943A/es not_active Application Discontinuation
- 2003-09-16 WO PCT/GB2003/003985 patent/WO2004024136A1/en not_active Ceased
- 2003-09-16 BR BR0317857-9A patent/BR0317857A/pt not_active IP Right Cessation
-
2005
- 2005-03-15 ZA ZA200502161A patent/ZA200502161B/en unknown
- 2005-03-15 IS IS7744A patent/IS7744A/is unknown
- 2005-04-15 NO NO20051847A patent/NO20051847L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ538793A (en) | 2007-05-31 |
| ZA200502161B (en) | 2005-09-15 |
| US20060135608A1 (en) | 2006-06-22 |
| CN1694694A (zh) | 2005-11-09 |
| PL375726A1 (en) | 2005-12-12 |
| WO2004024136A1 (en) | 2004-03-25 |
| KR20050042823A (ko) | 2005-05-10 |
| EP1556028A1 (en) | 2005-07-27 |
| CA2499142A1 (en) | 2004-03-25 |
| BR0317857A (pt) | 2005-12-06 |
| JP2006503031A (ja) | 2006-01-26 |
| RS20050226A (sr) | 2007-09-21 |
| MXPA05002943A (es) | 2005-06-03 |
| AU2003269138A1 (en) | 2004-04-30 |
| GB0221480D0 (en) | 2002-10-23 |
| HRP20050245A2 (en) | 2005-10-31 |
| IS7744A (is) | 2005-03-15 |
| RU2330653C2 (ru) | 2008-08-10 |
| TW200410682A (en) | 2004-07-01 |
| RU2005107416A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061736L (no) | Krystallform av epotilon B | |
| ATE423559T1 (de) | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren | |
| AU2003295912A1 (en) | Electro-osmotic pumps and micro-channels | |
| DK1206474T3 (da) | Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer | |
| DE60111570D1 (de) | Isoindolin-1-on als glukokinaseaktivatoren | |
| BR0312785A (pt) | Tratamento de desordens relacionadas a tnf(alfa) | |
| SE0102315D0 (sv) | Compounds | |
| EA200601554A1 (ru) | Замещенные индол-о-глюкозиды | |
| EP1670450B8 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
| NO20052760D0 (no) | Fremgangsmate for behandling av kreft og beslektede fremgangsmater. | |
| ATE442148T1 (de) | Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren | |
| IS8071A (is) | Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum | |
| MXPA02007099A (es) | Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina. | |
| NO20071378L (no) | Tiazolo-naftylsyrer. | |
| NO20024240D0 (no) | Nye arylfruktose-1,6-bisfosfataseinhibitorer | |
| AU2002358390A1 (en) | Novel compounds | |
| NO20053042L (no) | Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi. | |
| BR0317857A (pt) | Tratamento de anorexia nervosa (an) e bulimia | |
| BR0315644A (pt) | Piperazinil e diazapanil benzamidas e benzotioamidas | |
| NO20010860L (no) | Nye forbindelser | |
| NO20056161L (no) | Formuleringer for behandling av artrittilstander | |
| GB2399019B (en) | The structure containing the conductive medium for the source of the external high-power focusing ultrasonic treatment | |
| NO20055741D0 (no) | Nye kjemiske forbindelser | |
| ATE326968T1 (de) | Pharmazeutische zusammensetzung enthaltend tenatoprazol und einen entzündungshemmer | |
| IS7858A (is) | Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |